Full-Time
Data Management Senior Associate
Updated on 8/7/2026
Amgen
10,001+ employees
Biotech company creating biologic medicines
No salary listed
Hyderabad, Telangana, India
In Person
Bachelor's, Master's, Associate's
 Data & Analytics (1) |
|---|
Get referred to Amgen
See people who can refer or advise you
- A master's degree, or a bachelor's degree and 2 years of clinical execution experience, or an associate's degree and 6 years of clinical execution experience, or a high school diploma/GED and 8 years of clinical execution experience.
- Three years of work experience in a life sciences or medically related field, including one year of biopharmaceutical clinical research experience working on clinical trials in a biotechnology, pharmaceutical, or contract research organization company.
- Experience working in Data Management on global clinical trials.
- Execute study data management tasks including database build testing, data cleaning, query management, reconciliation, and lock preparation with limited oversight.
- Support Data Delivery Leads, Database Designers, and Data Acquisition Leads by owning time-sensitive deliverables with high-quality execution.
- Contribute to the setup and maintenance of electronic data capture and non-case-report-form data structures, including local laboratories, coding dictionaries, and non-case-report-form data integrations.
- Track progress against data-management timelines, study timelines, and deliverables; identify risks or delays; and escalate issues with clear documentation and mitigations.
- Coordinate with local internal teams, global team members, and external partners, including functional service providers, to ensure aligned and efficient delivery of study activities.
- Identify opportunities to improve repeatable processes and contribute to best practices and knowledge sharing across the team.
Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.
Company Size
10,001+
Company Stage
IPO
Headquarters
Thousand Oaks, California
Founded
1980
Get referred to Amgen
See people who can refer or advise you
Simplify's Take
What believers are saying
- Amgen raised 2026 revenue guidance to $38.2 billion-$39.4 billion on August 5, 2026.
- Repatha grew 37%, Evenity 38%, and Uplizna 90% in Q2 2026.
- MariTide entered broad Phase 3 testing, including switching studies from semaglutide and tirzepatide.
What critics are saying
- FDA proposed Tavneos withdrawal on April 30, 2026, threatening roughly $600 million annual sales.
- Enbrel sales fell 4% in Q2 2026 as Medicare Part D price setting bit.
- AMG 513 ended, AMG 193 ended, and MariTide waits until 2027 data.
What makes Amgen unique
- Amgen’s six growth drivers produced nearly 70% of Q2 2026 product sales.
- Repatha, Evenity, and Uplizna deliver double-digit growth across cardiovascular, bone, and rare-disease markets.
- Amgen generated $3.5 billion free cash flow in Q2 2026, funding R&D and dividends.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Conference Attendance Budget
Company News
Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.
Amgen reported second quarter 2026 revenues of $10.1 billion, a 10% increase year-over-year. Product sales grew 9%, driven by volume growth across 22 products that achieved double-digit sales growth. The company's six key growth drivers grew 26% year-over-year, generating nearly 70% of second quarter product sales. GAAP earnings per share increased 65% to $4.37, whilst non-GAAP EPS rose 4% to $6.29. Notable product performance included Repatha sales increasing 37% to $953 million and EVENITY growing 38% to $714 million. The company generated $3.5 billion in free cash flow, compared to $1.9 billion in the prior year period. For full year 2026, Amgen expects total revenues between $38.2 billion and $39.4 billion, with non-GAAP EPS guidance of $22.30 to $23.50.
Amgen secured a preliminary injunction in early June 2026 blocking Colorado's proposed 70% price cap on Enbrel, its rheumatoid arthritis drug. The federal judge's decision preserves pricing flexibility for the legacy asset. However, the company initiated several voluntary Class II recalls of Corlanor and Sensipar batches in the US due to foreign substances and manufacturing deviations. While not yet financially material, the recalls highlight ongoing operational risks. Amgen's investment case depends on its diversified portfolio offsetting pricing pressure and biosimilar competition. The company projects revenue of $40.1 billion and earnings of $9.9 billion by 2029, requiring 2.5% annual revenue growth. Current 2026 guidance stands at $37.1–$38.5 billion in revenue. The combination of pricing relief and quality concerns presents investors with a rebalanced risk-reward profile for the biotech company.
The New England Journal of Medicine has retracted the 2021 clinical trial that supported approval of Amgen's Tavneos, a treatment for ANCA-associated vasculitis that generated $459 million in sales last year. The retraction followed an FDA investigation revealing that results from nine patients were altered after the study database was finalised, whilst some researchers had been unblinded. The FDA alleges the original data showed no statistically significant difference between Tavneos and existing treatments, but subsequent changes made the drug appear more effective. The agency proposed withdrawing Tavneos from the US market in April, whilst European regulators have also recommended removal. Amgen, which acquired ChemoCentryx for $3.7 billion in 2022, continues selling Tavneos and has requested an FDA hearing. The company says it is engaging independent researchers to reanalyse the data.
A Delaware jury ruled in June 2026 that Amgen and its subsidiary Teneobio willfully infringed Harbour BioMed's Grosveld patent, awarding Harbour $20.2 million in damages with the possibility of tripling that amount to $60.6 million. Whilst the verdict raises questions about Amgen's antibody discovery platforms and intellectual property exposure, the potential damages appear modest against Amgen's $37.1 billion to $38.5 billion revenue guidance. The ruling comes as Amgen received European Commission approval for IMDYLLTRA for extensive stage small cell lung cancer, supporting its oncology innovation narrative. Analysts project Amgen will reach $40.1 billion in revenue and $9.9 billion in earnings by 2029, requiring 2.5 per cent annual revenue growth. The patent dispute may prompt reassessment of whether Amgen can scale high-margin launches without increased legal risk.